Dmso Containing Patents (Class 514/936)
-
Patent number: 9000013Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.Type: GrantFiled: September 9, 2013Date of Patent: April 7, 2015Inventor: Alfred A. Nickel
-
Patent number: 8530502Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.Type: GrantFiled: May 8, 2009Date of Patent: September 10, 2013Assignee: Dr. N's Health Care Products, LLCInventor: Alfred A. Nickel
-
Patent number: 7666914Abstract: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment which comprise applying the various disclosed combinations of agents to the patient's skin.Type: GrantFiled: June 3, 2004Date of Patent: February 23, 2010Inventors: David M. Richlin, George R. Doherty
-
Patent number: 7550488Abstract: The present invention discloses methods of application employing B5/B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.Type: GrantFiled: December 30, 2005Date of Patent: June 23, 2009Assignee: Dr. N's Health Care Products LLCInventor: Alfred A Nickel
-
Patent number: 7288533Abstract: A topical applications is used to treat and prevent the spread of nail infections or onychomycosis caused by bacteria, fungi and other pathogens. The topical application has a composition that comprises, as an active ingredient, at least one species selected from the group consisting of 2,2?-(alkyldioxy) bis-(alkyl-1,3,2-dioxaborinane) and 2,2?-oxybis(alkyl-1,3,2-dioxaborinane). More specifically, the composition comprises, as an active ingredient, at least one member selected from the group consisting of 2,2?-(1-methyltrimethylene dioxy) bis-(4-methyl-1,3,2-dioxaborinane) and 2,2?-oxybis (4,4,6-trimethyl-1,3,2-dioxaborinane).Type: GrantFiled: December 29, 2004Date of Patent: October 30, 2007Inventor: James Edward Brehove
-
Patent number: 7270834Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.Type: GrantFiled: June 3, 2002Date of Patent: September 18, 2007Inventors: Haydee Alba Stenti, Claudia Pirillo, Jose Maria Pastoriza
-
Patent number: 7241460Abstract: The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.Type: GrantFiled: September 27, 2002Date of Patent: July 10, 2007Assignee: Santosolve ASInventors: Egil Jellum, Bjørn Jarl Fagerlund, Clas Magne Kjølberg, Jo Klaveness
-
Patent number: 7078060Abstract: Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: February 12, 2003Date of Patent: July 18, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert E. Burrell, John B. Wright, Kan Lam, Hua Qing Yin, Antony G. Naylor, Peter H. Moxham, Scott H. Gillis, Paul Schechter
-
Patent number: 6399658Abstract: L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, metformin, phenformin, buformin, nalidixic acid, hopantenic acid, azidothymidine, dideoxycytidine, high caloric transfusion, propylene glycol, ethylene glycol, xylitol, lactose, sorbitol or the like.Type: GrantFiled: June 9, 1999Date of Patent: June 4, 2002Assignee: Sumitomo Pharmaceuticals Co., Ltd.Inventors: Hiroshi Noguchi, Mutsuo Taiji, Hiroshi Yamaga, Yasushi Itakura, Junji Ichihara
-
Patent number: 6316428Abstract: The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.Type: GrantFiled: August 26, 1999Date of Patent: November 13, 2001Inventor: Wilson Trafton Crandall
-
Patent number: 6241993Abstract: Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the &agr;-hydroxy and &bgr;-hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one bradykinin antagonist.Type: GrantFiled: June 1, 1998Date of Patent: June 5, 2001Assignee: Societe L'Oreal S.A.Inventors: Lionel Breton, Olivier De Lacharriere
-
Patent number: 6017948Abstract: Disclosed are compositions comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent, together with kits comprising the composition and methods of using the composition.Type: GrantFiled: October 30, 1998Date of Patent: January 25, 2000Assignee: Supergen, Inc.Inventors: Joseph Rubinfeld, Ashok Y. Gore, Rajashree Joshi, Rajesh Shrotriya
-
Patent number: 6010691Abstract: The permeation of a therapeutic agent through the epithelium by topical administration is enhanced by the further topical administration of a stearylamine, transvaccenic acid or a combination of a stearylamine and transvaccenic acid.Type: GrantFiled: April 26, 1996Date of Patent: January 4, 2000Assignees: The Regents of the University of California, Cellegy Pharmaceuticals, Inc.Inventors: Carl R. Thornfeldt, Peter M. Elias, Stephen Grayson
-
Patent number: 5952392Abstract: Therapeutic compositions including a nonionic surfactant combined with long chain fatty acids, alkanes, amides or mono-unsaturated alcohols, particularly stearyl alcohol, erucyl alcohol, brassidyl alcohol, arachidyl alcohol, n-docosane, n-docosanoic acid, erucamide and stearic acid, or mixtures thereof, as active ingredients are disclosed. Methods of preventing or treating viral infections, treating skin or membrane inflammation or inhibiting cell proliferation using such compositions are disclosed.Type: GrantFiled: August 22, 1997Date of Patent: September 14, 1999Assignee: Avanir PharmaceuticalsInventors: David H. Katz, Laura E. Pope, Mohammed H. Khalil, John F. Marcelletti, Lee R. Katz
-
Patent number: 5945409Abstract: The present invention comprises methods and compositions for topically treating and moisturizing keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.Type: GrantFiled: June 16, 1997Date of Patent: August 31, 1999Assignee: Wilson T. CrandallInventor: Wilson Trafton Crandall
-
Patent number: 5939072Abstract: An herbal treatment composition includes a combination of mushroom derived polysaccharides wherein the polysaccharides are derived from at least two mushrooms from the group consisting of Maitake, Shiitake, Reishi, Poria, Cordyceps and Hericium.Type: GrantFiled: May 13, 1998Date of Patent: August 17, 1999Inventors: James H. Zhou, Youwei Wang
-
Patent number: 5885565Abstract: A method for enhancing penetration of a therapeutic or prophylactic agent in a host in need of the topical administration thereof which comprises applying to the epithelium of the host, an effective amount of one or more penetration enhancing epithelial sterols and the therapeutic or prophylactic agent.Type: GrantFiled: April 26, 1996Date of Patent: March 23, 1999Assignees: Cellegy Pharmaceuticals Inc., The Regents of the University of CaliforniaInventors: Peter M. Elias, Stephen Grayson, Carl R. Thornfeldt
-
Therapeutic/cosmetic compositions comprising bradykinin antagonist for treating sensitive human skin
Patent number: 5849312Abstract: Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the .alpha.-hydroxy and .beta.-hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one bradykinin antagonist.Type: GrantFiled: July 31, 1996Date of Patent: December 15, 1998Assignee: Societe L'Oreal S.A.Inventors: Lionel Breton, Olivier De Lacharriere -
Patent number: 5741527Abstract: The present invention relates to novel veterinary topical compositions, methods of making the compositions, and methods of using the compositions in the treatment of bone, muscle and connective tissue injuries, as well as respiratory ailments, in animals, particularly horses, dogs, and goats. The compositions comprise isopropyl alcohol, mercuric chloride and dimethylsulfoxide (DMSO), and may further comprise herbs. Light training can typically be resumed beginning about 24 hours after applying the composition to the injured area of the animal.Type: GrantFiled: February 18, 1997Date of Patent: April 21, 1998Inventor: Paul K. Brown
-
Patent number: 5738839Abstract: The present invention relates to gelled emulsion particles obtained when predetermined volumes, especially drops, of an emulsion with an aqueous external phase, containing an appropriate reagent in solution in the said aqueous phase, are added to a gelling solution and left therein for a period of time which depends on the degree of gelling desired for the said particles.It further relates to compositions--especially solutions, gels or emulsions with an aqueous external phase--in which the said particles are present.Type: GrantFiled: June 6, 1995Date of Patent: April 14, 1998Assignee: Helene Rubenstein, Inc.Inventors: Anne Clement, Pierre Fodor, Gerard Guth, Nathalie Thiollet
-
Patent number: 5639740Abstract: The present invention comprises methods and compositions for topically treating keratinous structures of humans and animals including skin, hair, fingernails, toenails, hooves, and horns.Type: GrantFiled: March 10, 1995Date of Patent: June 17, 1997Inventor: Wilson Trafton Crandall
-
Patent number: 5573772Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptor.Type: GrantFiled: March 17, 1994Date of Patent: November 12, 1996Assignees: Gensia, Inc., South Alabama Medical Science FoundationInventors: James M. Downey, Kevin M. Mullane
-
Patent number: 5560916Abstract: A cosmetic or dermatological composition for use in the treatment of ageing of the skin is provided which contains vinegar as the active anti-ageing agent in a cosmetically or dermatologically acceptable carrier, along with a method for the treatment of ageing, exemplified by wrinkles and/or lines and/or blemishes, using the composition.Type: GrantFiled: February 3, 1995Date of Patent: October 1, 1996Assignee: L'OrealInventors: Constantin Koulbanis, Myriam Mellul, Didier Candau
-
Patent number: 5516526Abstract: This invention relates to a method of protection from and treatment of neurological damage in mammals by administration of dimethylsulfoxide (DMSO) in combination with fructose 1,6-diphosphate (FDP). The effects of administration of the drugs together, either as two separate compositions or in combination, results in synergistic action that greatly improves protection from morbidity in animals (including humans) who have suffered injury to the brain.Type: GrantFiled: March 22, 1995Date of Patent: May 14, 1996Inventor: Jack da la Torre
-
Patent number: 5508022Abstract: The present invention relates to gelled emulsion particles obtained when predetermined volumes, especially drops, of an emulsion with an aqueous external phase, containing an appropriate reagent in solution in the said aqueous phase, are added to a gelling solution and left therein for a period of time which depends on the degree of gelling desired for the said particles.It further relates to compositions--especially solutions, gels or emulsions with an aqueous external phase--in which the said particles are present.Type: GrantFiled: October 31, 1994Date of Patent: April 16, 1996Assignee: Helena Rubinstein Inc.Inventors: Anne Clement, Pierre Fodor, Gerard Guth, Nathalie Thiollet, married name Lilienthal
-
Patent number: 5457123Abstract: The invention relates to a process for the solubilization in a non-ionic surface-action agent of from between about 0.001 mg and about 1 mg of forskolin, to the pharmaceutical compositions based on such solubilized forskolin and to the use of these in the treatment of various diseases and disorders and maladies in mammals, including humans. Forskolin is 7-beta-acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-o ne.Type: GrantFiled: June 1, 1994Date of Patent: October 10, 1995Inventor: Jeffery J. Feigenbaum
-
Patent number: 5443836Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptors.Type: GrantFiled: March 15, 1993Date of Patent: August 22, 1995Assignees: Gensia, Inc., South Alabama Medical Science FoundationInventors: James M. Downey, Kevin Mullane
-
Patent number: 5415855Abstract: Modified ceramides are defined, together with their synthesis and compositions comprising them for topical application to human skin, hair and nails. The modified pseudoceramides have a structure: ##STR1## and an approximate summary is that R and R.sup.1 are aliphatic hydrocarbon, A is CH.sub.2, CHOR.sup.2, CH.dbd.CH or CHOY, and at least one of R.sup.2, R.sup.3 and R.sup.4 is sulphate, phosphate or similar. The presence of phosphate or sulphate facilitates skin absorption, after which the phosphate or sulphate is removed by enzymes present in vivo.Type: GrantFiled: June 22, 1993Date of Patent: May 16, 1995Assignee: Elizabeth Arden Co., Division of Conopco, Inc.Inventors: Peter Critchley, Susan E. Kirsch, Anthony V. Rawlings, Ian R. Scott
-
Patent number: 5298257Abstract: A preparation for the once-daily, percutaneous administration of nicotine comprises nicotine uniformly distributed in a solid, semi-solid or mucilaginous medium which can be placed in intimate contact with the skin, the solid, semi-solid or mucilaginous medium is formed by adding a given amount of nicotine to a solution of a solidifying or gel-forming agent or mixture thereof in a suitable solvent or mixture of solvents and mixing or heating the mixture thereby obtained so as to form the solid, semi-solid or mucilaginous medium. The preparation can be used in a method of treating withdrawal symptoms associated with smoking cessation and for combating the psychological dependence that occurs through frequent smoking.Type: GrantFiled: March 19, 1992Date of Patent: March 29, 1994Assignee: Elan Transdermal LimitedInventors: Yvonne B. Bannon, John Corish, Owen I. Corrigan, Edward J. Geoghegan, Joseph G. Masterson
-
Patent number: 5122540Abstract: A solution of DMSO and a body reactive agent (such as citric acid) is provided, and is typically topically applied to the body, as to a wart or to the skin of the throat.Type: GrantFiled: January 22, 1990Date of Patent: June 16, 1992Assignees: W. Keith R. Watson, Walter B. Dandliker, William W. HaefligerInventors: W. Keith R. Watson, Walter B. Dandliker
-
Patent number: 5096893Abstract: A method for obtaining a desired pattern of substitution of hydroxyalkyl groups on cyclodextrins which comprises controlling the basicity of a reaction mixture comprising epoxide and cyclodextrins and a suitable solvent. Through the proper control of basicity with, e.g., sodium hydroxide, hydroxyalkyl substitution may be directed either toward the narrow or wide opening of the cavity of cyclodextrins.Type: GrantFiled: December 17, 1990Date of Patent: March 17, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Josef Pitha, Bengt Lindberg
-
Patent number: 5091180Abstract: The present invention is directed to the in vivo use of compounds which prevent the generation of, effectively scavenge, or detoxify a reactive oxygen metabolite that mediates a toxic effect of rhabdomyolysis and myoglobinuria. The compounds of the invention can be used to prevent or reduce rhabdomyolysis-induced renal damage, and include but are not limited to free radical scavengers, iron chelators, oxidizable compounds, enzymes which metabolize reactive oxygen metabolites or their precursors, and biosynthetic precursors thereof.Type: GrantFiled: November 30, 1990Date of Patent: February 25, 1992Assignee: Administrators of the Tulane Educational FundInventors: Patrick D. Walker, Sudhir V. Shah
-
Patent number: 5085868Abstract: A dosage form for oral administration of a pharmaceutically active substance characterized in that it includes a encapsulated or embedded pharmaceutically active substance in a pharmaceutically acceptable non-aqueous liquid.Type: GrantFiled: September 17, 1990Date of Patent: February 4, 1992Assignee: Astra Lakemedel AktiebolagInventors: Kjell J. Mattsson, Alf G. M. Nicklasson, Rolf Sjoovist
-
Patent number: 5070107Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.Type: GrantFiled: November 2, 1989Date of Patent: December 3, 1991Assignee: Lidak PharmaceuticalsInventor: David H. Katz
-
Patent number: 5057518Abstract: The synthesis and application of N(1)-n-alkyl-pyrimidinium-salts are described. These surfactants have a very small critical micelle concentration (CMC) in the order of 10.sup.-5 -10.sup.-7 Mol/Liter. These N(1)-n-alkyl-pyrimidinium components have pharmacological activities and can act as antimetabolites.Type: GrantFiled: May 24, 1990Date of Patent: October 15, 1991Assignee: Medice Hem.-Pharm. Fabrik Putter GmbH & Co. KGInventor: Henrich H. Paradies
-
Patent number: 5032613Abstract: A solution of DMSO and a body reactive agent (such as citric acid) is provided, and is typically topically applied to the body.Type: GrantFiled: February 5, 1990Date of Patent: July 16, 1991Assignees: W. Keith R. Watson, William W. HaefligerInventor: W. Keith R. Watson
-
Patent number: 4946853Abstract: A preparation for the once-daily, percutaneous administration of nicotine comprises nicotine uniformly distributed in a solid, semi-solid or mucilaginous medium which can be placed in intimate contact with the skin, the solid, semi-solid or mucilaginous medium is formed by adding a given amount of nicotine to a solution of a solidifying or gel-forming agent or mixture thereon in a suitable solvent or mixture of solvents and mixing or heating the mixture thereby obtained so as to form the solid, semi-solid or mucilaginous medium.The preparation can be used in a method of treating withdrawal symptoms associated with smoking cessation and for combating the psychological dependence that occurs through frequency smoking.Type: GrantFiled: April 29, 1988Date of Patent: August 7, 1990Assignee: Elan Transdermal LimitedInventors: Yvonne B. Bannon, John Corish, Owen I. Corrigan, Edward J. Geoghegan, Joseph G. Masterson
-
Patent number: 4943307Abstract: The invention relates to a plant-protective solution containing 2.5 to 40 % by weight of one or more water-insoluble plant-protective ingredient(s) 20 to 71.5 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 10 to 71.5 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 1 to 15 % by weight of commonly used additives such as anionic and/or nonionic surface active agents and macromolecules.The invention also relates to the ready-for-use plant-protective suspension containing 0.2 to 10 % by weight of one or more water-insoluble plant-protective ingredient(s) with a particle size of 0.1 to 50 .mu.m, 0 to 60 % by weight of a fertilizer, 0.2 to 10 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 0.2 to 10 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 0.05 to 2.Type: GrantFiled: July 15, 1988Date of Patent: July 24, 1990Assignee: Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt.Inventors: Tamas Detre, Sandor ngyan, Laszlo Pap, Andras Szego, Zoltan Karadi, Klara Bertus nee Bende, Katalin Marmarosi nee Kellner
-
Patent number: 4937230Abstract: Methods are disclosed for enhancing the healing of a variety of wounds in horses. The methods generally comprise administering to the wound a therapeutically effective amount of a composition comprising GHL:Cu or a derivative thereof in combination with a physiologically acceptable carrier or diluent.Type: GrantFiled: December 4, 1987Date of Patent: June 26, 1990Assignee: ProCyte CorporationInventor: Loren R. Pickart
-
Patent number: 4927641Abstract: A liniment for treating bowed tendons in horses comprises dimethylsulfoxide (DMSO) and an alkali metal hypochlorite, preferably sodium hypochlorite. The liniment is preferably a thin liquid but may be in the form of a lotion, gel or cream. The liniment is applied to the skin surrounding a damaged equine tendon.Type: GrantFiled: May 23, 1989Date of Patent: May 22, 1990Inventor: Gerald L. Knight
-
Patent number: 4898884Abstract: A solution of DMSO and a body reactive agent (such as citric acid) is provided, and is typically topically applied to the body.Type: GrantFiled: February 16, 1986Date of Patent: February 6, 1990Assignees: Kenneth R. Watson, William W. HaefligerInventor: W. Keith R. Watson
-
Patent number: 4886671Abstract: Dutch elm disease is counteracted by injecting elm trees susceptible to, or having such disease, with a composition comprising a water soluble zinc salt dissolved in water and mixed with dimethyl sulfoxide in certain predetermined proportions, preferably applied at a time when the sap is returning to the root system.Type: GrantFiled: October 25, 1984Date of Patent: December 12, 1989Inventor: John Cryer
-
Patent number: 4871767Abstract: Medicament preparations contain 2-(2-hydroxyethoxy)-ethyl N-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-anthranilate and dimethyl sulphoxide.Type: GrantFiled: September 4, 1987Date of Patent: October 3, 1989Assignee: Troponwerke GmbH & Co, KGInventors: Bernhard Beckermann, Hans-Dieter Dell, Harald Horstmann, Reinhold Kraus
-
Patent number: 4833158Abstract: This invention provides a method of combating termites at a locus, which comprises treating the locus e.g. soil or timber with an acyl urea of the formula ##STR1## wherein one substituent X is a halogen atom or a merthyl group and the other is a halogen atom, a hydrogen atom or a methyl group, and each of R.sup.1, R.sup.2 and R.sup.3 independently represents a hydrogen or fluorine atom; the use of acyl ureas of formula I for combating termites; and compositions for protecting timber against termite attack.Type: GrantFiled: December 17, 1987Date of Patent: May 23, 1989Assignee: Shell Internationale Research Maatschappij B.V.Inventors: Roland S. Twydell, Jennifer M. Radcliffe
-
Patent number: 4760051Abstract: A method of enhancing the wound-healing process in animals utilizing glycyl-1-histidyl-1-lysine: copper(II) (GHL-Cu) is disclosed. GHL-Cu functions as a superoxide dismutase which detoxifies tissue-damaging oxygen radicals, but does not evoke an antigenic response. A method of treating inflammatory conditions in animals and a method of reducing the traumatic effects in animals occurring subsequent to major tissue damage utilizing GHL-Cu is also disclosed.Type: GrantFiled: January 24, 1985Date of Patent: July 26, 1988Inventor: Loren R. Pickart
-
Patent number: 4747845Abstract: A synthetic resin matrix system for the delayed and extended duration delivery of drugs to humans and animals is disclosed consisting of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen binding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The plasticizer also has a direct shortening effect upon the cure time and also profoundly influences many of the physical characteristics of the resultant synthetic resin matrix system. A variety of drugs can be embodied in the fabricated matrix system and administered to the patient (or animal) by different modes of application, including but not limited to oral, topical, rectal, subcutaneous implant, or organ-specific implant such as in the conjunctival sac of the eye.Type: GrantFiled: January 3, 1986Date of Patent: May 31, 1988Assignee: Enquay Pharmaceutical AssociatesInventor: Bernard Korol
-
Patent number: 4725271Abstract: A synthetic resin matrix dressing is disclosed consisting essentially of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen bonding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The dressing may be applied to the treatment site in veterninary use in the form of a paste for the in-situ curing or setting thereof, or the dressing may be preformed and then applied to the treatment site. A variety of drug agents may be incorporated in the synthetic resin matrix so as to result in the time released administration of the drug agent to the area of the skin covered by the dressing. A method of treatment using this dressing is also disclosed.Type: GrantFiled: November 27, 1985Date of Patent: February 16, 1988Assignee: Enquay Pharmaceutical AssociatesInventor: Bernard Korol
-
Patent number: 4689230Abstract: Plant extracts are employed to provide a menses inducing composition for topical application. Common commercially available fenugreek seeds and commercially available ginger are mixed in a preferred range of ratios and combined in a dry powder form for topical application to the outside of the abdomen of the female to induce menses.Type: GrantFiled: December 15, 1983Date of Patent: August 25, 1987Assignee: John B. SowellInventor: Nabeel H. Ayoub
-
Patent number: 4684630Abstract: A method of parenterally delivering aqueously unstable drugs that includes the aqueous dilution of a stable, anhydrous organic solution having the drug dissolved therein. The resulting organic-aqueous solution is physiologically suitable for parenteral delivery into a warm-blooded mammal and contains the drug in an effective dosage concentration per unit volume.Type: GrantFiled: April 4, 1985Date of Patent: August 4, 1987Inventors: Arnold J. Repta, Parviz Mojaverian
-
Patent number: 4652557Abstract: Novel pharmaceutical solutions and particularly novel pharmaceutical solutions comprising dimethyl sulfoxide (DMSO).Type: GrantFiled: October 24, 1985Date of Patent: March 24, 1987Assignee: Clark Pharmaceutical Laboratories Ltd.Inventor: Edmund Sandborn